NCT01512420View on ClinicalTrials.gov

An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT)

CompletedOBSERVATIONAL

Enrollment

355

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Trial Locations (41)

10003

Cáceres

15006

A Coruña

15706

Santiago de Compostela

17007

Girona

20080

Donostia / San Sebastian

22004

Huesca

22300

Barbastro

24071

León

26006

Logroño

27003

Lugo

28007

Madrid

28040

Madrid

28046

Madrid

28805

Alcalá de Henares

28905

Madrid

33011

Oviedo

35020

Las Palmas de Gran Canaria

37007

Salamanca

38320

San Cristóbal de La Laguna

39008

Santander

41014

Valencia

43204

Reus

44002

Teruel

45004

Toledo

46015

Valencia

46017

Valencia

46026

Valencia

46800

Xàtiva

47005

Valladolid

48013

Bilbao

49021

Zamora

50009

Zaragoza

52005

Melilla

01009

Vitoria-Gasteiz

03600

Elda

07703

Mahon

07014

Palma de Mallorca

08006

Barcelona

08036

Barcelona

08041

Barcelona

08916

Barcelona

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01512420 - An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT) | Biotech Hunter | Biotech Hunter